Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in EOLS — Evolus, Inc.

CIK 1423053 MIAMI, FL
Back to EOLS Full portfolio

Position in EOLS

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$2,863,144
-$6,308,077 QoQ
Shares Held
696,629
-49.5% QoQ
Ownership
1.06%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in EOLS Over Time

Shares Held

Position Value (USD)

Derivatives in EOLS

reported options exposure · as of Mar 31, 2026
CallValue
$206,733
CallShares
50,300
PutValue
$166,044
PutShares
40,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $927,090,430 across 59 Drug Manufacturers - Specialty & Generic names. EOLS ranks #28 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 UTHR
UNITED THERAPEUTICS Corp
 360,643 $213,854,086
2 INDV
Indivior Pharmaceuticals, Inc.
 3,574,044 $108,936,860
3 ELAN
Elanco Animal Health Inc
 4,387,127 $104,983,948
4 ALKS
Alkermes plc.
 2,241,584 $79,262,409
5 SUPN
Supernus Pharmaceuticals, Inc.
 1,493,446 $77,196,223
6 ZTS
Zoetis Inc.
 501,011 $59,224,510
7 VTRS
Viatris Inc
 3,993,155 $53,947,523
8 KNSA
Kiniksa Pharmaceuticals International, plc
 474,750 $22,859,212

All Filings in EOLS

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $206,733 50,300
2026-03-31 $2,863,144 696,629
2026-03-31 $166,044 40,400
2025-12-31 $9,171,221 1,379,131
2025-12-31 $85,120 12,800
2025-12-31 $256,025 38,500
2025-09-30 $203,234 33,100
2025-09-30 $3,612,831 588,409
2025-06-30 $445,764 48,400
2025-06-30 $97,626 10,600
2025-06-30 $5,358,920 581,859
2025-03-31 $333,231 27,700
2025-03-31 $101,052 8,400
2025-03-31 $2,977,099 247,473
2024-12-31 $27,600 2,500
2024-12-31 $303,600 27,500
2024-12-31 $684,159 61,971
2024-09-30 $309,420 19,100
2024-09-30 $2,446,993 151,049
2024-09-30 $16,200 1,000
2024-06-30 $399,280 36,800
2024-06-30 $695,658 64,116
2024-06-30 $148,645 13,700
2024-03-31 $1,045,800 74,700
2024-03-31 $877,548 62,682
2024-03-31 $130,200 9,300
2023-12-31 $1,802,903 171,216
2023-12-31 $73,710 7,000
2023-12-31 $214,812 20,400
2023-09-30 $320,585 35,075
2023-09-30 $128,874 14,100
2023-09-30 $420,440 46,000
2023-06-30 $2,207,753 303,680
2023-06-30 $53,071 7,300
2023-06-30 $101,053 13,900
2023-03-31 $144,666 17,100
2023-03-31 $37,224 4,400
2023-03-31 $1,562,739 184,721
2022-12-31 $554,117 73,784
2022-12-31 $710,446 94,600
2022-12-31 $81,859 10,900
2022-09-30 $792,925 98,500
2022-09-30 $1,697,245 210,838
2022-06-30 $1,286,440 110,900
2022-06-30 $5,172,474 445,903
2022-06-30 $116,000 10,000
2022-03-31 $2,822,963 251,601
2022-03-31 $1,229,712 109,600
2021-12-31 $828,461 127,260
2021-12-31 $609,336 93,600

Report a Problem

Category
Description
Email (optional, for follow-up)